-
Je něco špatně v tomto záznamu ?
Rising incidence of Mycoplasma pneumoniae pneumonias in a tertiary paediatric centre: implications for antibiotic therapy
L. Bača, L. Slováková, J. Vočková, K. Doležalová
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Digitální knihovna NLK
Zdroj
NLK
Free Medical Journals
od 2004
ProQuest Central
od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
PubMed
40293833
DOI
10.21101/cejph.a8434
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky * terapeutické užití MeSH
- centra terciární péče MeSH
- dítě MeSH
- hospitalizace statistika a číselné údaje MeSH
- incidence MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- Mycoplasma pneumoniae MeSH
- mykoplazmová pneumonie * epidemiologie farmakoterapie MeSH
- předškolní dítě MeSH
- retrospektivní studie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: The aim of this study is to determine the incidence of Mycoplasma pneumoniae pneumonia (MPP) in children and adolescents in Prague, Czech Republic, between January and July 2024, and to compare the findings with data from the preceding period. METHODS: A retrospective analysis of data of paediatric patients at our single tertiary care facility was conducted. Two distinct patient cohorts were subjected to analysis: the first comprising individuals who had been hospitalised between January 2019 and July 2024, and the second consisting of outpatients who had been treated during the periods of January to July 2023 and January to July 2024. RESULTS: A 12.3-fold increase in the number of outpatients diagnosed with MPP was observed between January and July 2024 in comparison to the same period in 2023, with 111 cases reported in 2024 versus 9 cases in 2023. A total of 23 patients were hospitalised with MPP between January 2019 and July 2024, with 15 of these hospitalisations having occurred between January and July 2024. The median age was 12 years, with an age range of 1 to 17 years. The majority of cases presented with a high fever, chest pain, and required oxygen support. A failure of the clarithromycin treatment was observed, resulting in 19.48% of doxycycline prescriptions being issued due to a prior failure of clarithromycin treatment. During the monitoring period, no cases of treatment failure with doxycycline were documented. CONCLUSION: The present study demonstrates an emerging trend of increased incidence of Mycoplasma pneumoniae pneumonia in the paediatric population during the initial seven months of 2024 in the Czech Republic. Doxycycline has been demonstrated to be the optimal antibiotic for the treatment of MPP and in accordance with the prevailing practice in other states it should be included in the therapeutic regimen even in children under the age of eight. The authors put forward recommendations for the implementation of measures aimed at reducing the negative impact of MPP on public health.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25011612
- 003
- CZ-PrNML
- 005
- 20250527091426.0
- 007
- ta
- 008
- 250506s2025 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a8434 $2 doi
- 035 __
- $a (PubMed)40293833
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Bača, Ľuboš $u Department of Paediatrics, First Faculty of Medicine, Charles University, and Thomayer University Hospital, Prague, Czech Republic $7 xx0253625
- 245 10
- $a Rising incidence of Mycoplasma pneumoniae pneumonias in a tertiary paediatric centre: implications for antibiotic therapy / $c L. Bača, L. Slováková, J. Vočková, K. Doležalová
- 520 9_
- $a OBJECTIVES: The aim of this study is to determine the incidence of Mycoplasma pneumoniae pneumonia (MPP) in children and adolescents in Prague, Czech Republic, between January and July 2024, and to compare the findings with data from the preceding period. METHODS: A retrospective analysis of data of paediatric patients at our single tertiary care facility was conducted. Two distinct patient cohorts were subjected to analysis: the first comprising individuals who had been hospitalised between January 2019 and July 2024, and the second consisting of outpatients who had been treated during the periods of January to July 2023 and January to July 2024. RESULTS: A 12.3-fold increase in the number of outpatients diagnosed with MPP was observed between January and July 2024 in comparison to the same period in 2023, with 111 cases reported in 2024 versus 9 cases in 2023. A total of 23 patients were hospitalised with MPP between January 2019 and July 2024, with 15 of these hospitalisations having occurred between January and July 2024. The median age was 12 years, with an age range of 1 to 17 years. The majority of cases presented with a high fever, chest pain, and required oxygen support. A failure of the clarithromycin treatment was observed, resulting in 19.48% of doxycycline prescriptions being issued due to a prior failure of clarithromycin treatment. During the monitoring period, no cases of treatment failure with doxycycline were documented. CONCLUSION: The present study demonstrates an emerging trend of increased incidence of Mycoplasma pneumoniae pneumonia in the paediatric population during the initial seven months of 2024 in the Czech Republic. Doxycycline has been demonstrated to be the optimal antibiotic for the treatment of MPP and in accordance with the prevailing practice in other states it should be included in the therapeutic regimen even in children under the age of eight. The authors put forward recommendations for the implementation of measures aimed at reducing the negative impact of MPP on public health.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mykoplazmová pneumonie $x epidemiologie $x farmakoterapie $7 D011019
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a antibakteriální látky $x terapeutické užití $7 D000900
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a centra terciární péče $7 D062606
- 650 _2
- $a Mycoplasma pneumoniae $7 D009177
- 650 _2
- $a hospitalizace $x statistika a číselné údaje $7 D006760
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Slováková, Lea $u Department of Paediatrics, First Faculty of Medicine, Charles University, and Thomayer University Hospital, Prague, Czech Republic $7 xx0314254
- 700 1_
- $a Vočková, Jitka $u Department of Paediatrics, First Faculty of Medicine, Charles University, and Thomayer University Hospital, Prague, Czech Republic $7 xx0332424
- 700 1_
- $a Doležalová, Karolína $u Department of Paediatrics, First Faculty of Medicine, Charles University, and Thomayer University Hospital, Prague, Czech Republic $7 xx0237719
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 33, č. 1 (2025), s. 77-79
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40293833 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20250506 $b ABA008
- 991 __
- $a 20250527091427 $b ABA008
- 999 __
- $a ok $b bmc $g 2324863 $s 1248702
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 33 $c 1 $d 77-79 $e - $i 1210-7778 $m Central European journal of public health $n Cent Eur J Public Health $x MED00001083
- LZP __
- $b NLK116 $a Pubmed-20250506